


## **HCP Consumer Research**

Prepared for: Palin Communications January 2012







# 1. Methodology



# Methodology

- ▶ This study was conducted online among a representative sample of Australians aged 18-64 years.
- ▶ The sample was 1,007 respondents, distributed throughout Australia including both capital city and non-capital city areas.
- Galaxy Research designed the questionnaire, a copy of which has been included in this report.
- ▶ The questionnaire was transferred into Quest format in order to be hosted online. For each question the respondent had to click on the response which represented their answer.
- ▶ Fieldwork commenced on Monday 9 January and was completed on Wednesday 11 January 2012.
- Following the completion of interviewing, the data was weighted by gender, age and area to reflect the latest population estimates.







# 2. Main Findings





### **Main Findings**

- ▶ There is widespread scepticism and little support for the current system in which pharmaceutical companies pay undisclosed fees to healthcare professionals. Overall, those that disapprove of these payments (44%) outnumber those that approve (21%) by a factor of two to one.
- Older Australians are especially concerned about the payments made by pharmaceutical companies. The majority of Baby Boomers (54%) disapprove of the payments, compared to 28% of Gen Y.
- Nine in 10 Australians have some concerns about pharmaceutical companies paying fees to healthcare professionals, with the biggest concern being the potential for the payments to influence the advice that doctors give to patients (72%).
- ▶ Others fear that the integrity of the doctor will be compromised as a result of the payment (54%) or that patients may not receive the best medicine (52%). Around half (51%) of the population simply view the payment as a form of bribery.
- ▶ When given further information about the purpose of the funding there is a significant shift in opinion. Overall, 79% approve of pharmaceutical companies helping fund medical research programs, 71% approve of their funding of clinical education projects and 59% approve of their funding of advisory committee work on new medicines.
- Overall, 82% of Australians approve of pharmaceutical companies funding some aspect of the health service
   when the purpose of the funding is explained. In contrast, just 18% oppose any type of funding.



### Main Findings .... continued

- Widespread support for pharmaceutical companies helping to fund medical research programs may be observed across the different demographic groups and all states of Australia.
- It is not that there is a complete lack of trust in the pharmaceutical industry, it is just that the community expects greater transparency in their dealings with health professionals. The view of the majority of Australians (64%) is that the payment of fees to healthcare professionals is acceptable as long as the pharmaceutical companies are completely open and publicly declare the fees paid.
- In order to make the payments more open to scrutiny, the majority (65%) would prefer that the pharmaceutical companies disclose each and every individual sponsorship of specific doctors and specialists. In contrast, only 23% would prefer a system in which the pharmaceutical companies reveal the total amount spent sponsoring healthcare professionals in general.
- ▶ The benefit of introducing greater transparency would be an improvement in the public standing of the pharmaceutical industry. Overall, 65% say they would view the industry more favourably if pharmaceutical companies were more open in their relationships with healthcare professionals.
- This improvement may be observed across all states and all demographic groups.







# 3. Questionnaire



GALAXY JOB NO. 120110 To be fielded no later than Wednesday, 11 January 2012

Thank you for agreeing to participate in this survey. Please answer the following questions to see if you fall into the category of respondent we need to interview. You will need to provide a response for EVERY question to proceed with the interview

Please be assured of complete confidentiality. Galaxy Research is bound by the Market Research Society Privacy Principles.

During the survey, please <u>do not</u> use your browser's **FORWARD** and **BACK** buttons. Instead, please always use the buttons below to move backward and forward through the survey.

#### Your honesty is valuable and really appreciated.

Galaxy Research appreciates that most people give honest answers in our surveys and we want to keep it that way. We encourage truthful answers by making our surveys easy to understand, easy to complete and short enough to keep you going.

There has however been some recent evidence of inconsistent and even falsified information through on-line surveys. To this end we again encourage you:

- 1. To fill in all survey invitations to you, yourself
- 2. To read and follow all survey instructions and questions
- 3. To give due consideration to all your answers, and of course,
- 4. To always give honest and truthful answers

Galaxy Research monitors closely the data collected by participants in its panel surveys and has taken steps (data range checks, registration verifications, question validations, time taken to complete etc) to detect any suspicious data.

Participant ID's suspected of providing dishonest or false information in our surveys will be forwarded to the panel provider and may not be rewarded or even excluded from future invitations.

We understand that you are most likely always honest and therefore we say thanks again and please keep responding to our surveys.

#### **SECTION A - ASK ALL RESPONDENTS**

| A1. | Where do you live in Australia? | NSW - Sydney   | Queensland -<br>South Austral<br>South Austral<br>Western Aust<br>Western Aust | Brisbane  |
|-----|---------------------------------|--|--|---|
| A2. | How old are you?                | 17 years or u<br>18-24 years<br>25-29 years<br>30-34 years<br>35-39 years<br>40-44 years | 02<br>03<br>04<br>05   | 45-49 years 07<br>50-54 years 08<br>55-59 years 09<br>60-64 years 10<br>65-69 years 11<br>70+ years 12<br>Rather not say 13 |

#### ASK IF AGED 18-64 YEARS IE CODE 02-10 IN A2. CODE 01, 11-13 TERMINATE WITH THANKS

| A3.    | And are you male or female?  |  | Male 1<br>Female 2                |
|--------|--|--|-----------------------------------|
| SECTIO | ON B – ASK ALL QUALIFYING RESPONDENTS  |  |                                   |
| B1.    | Each year pharmaceutical companies pay fees to health care doctors, medical associations and research institutes. Ove disapprove of the payment of these fees by pharmaceutical co   | rall, do you approve or  | Approve                           |
|        | Please select one option only  |  |                                   |
| B2.    | What concerns, if any, do you have about pharmaceuti companies paying fees to health care professionals? ROTATE 1-6 Please select all that apply   | the integrity of It is not monitore It is a form of bri It may influence advice doctors Secret payments inconsistent with  | the doctor                        |
|        |  |  | best medicine6 ve7                |
| B3.    | <ul><li>B. Helping fund clinical</li><li>C. Funding advisory</li></ul>   | t to use them. Please indicate ost of each of the following.   |                                   |
| B4.    | Which of these options best describes your view about pharmaceutical companies paying fees to health care professionals?  Please select one option only  | It is OK because I trust the pharmaceutical companies It is acceptable as long it is copen and the fees are publi It is not acceptable under any None of the above | ompletely cly declared2           |
| B5.    | There are two ways to make these payments more open to scrutiny. The pharmaceutical companies could reveal the <b>total amount</b> spent sponsoring healthcare professionals in general or they could disclose <b>each and every</b> individual sponsorship of specific doctors and specialists. On balance, which of these options would you prefer?  Please select one option only | Reveal <b>total amount</b> spent sponsoring healthcare Disclose <b>each and every</b> incomposed sponsorship of specific door                                      | lividual<br>fors and specialists2 |

B6. If pharmaceutical companies decided to be more open in their relationships with healthcare professionals and began to publicly View much more favourably...... 1 declare the details behind these sponsorships of healthcare professionals, would this make you view pharmaceutical companies View somewhat more favourably .... 2 more favourably, less favourably or would this not change your Not change opinion......3 opinion of pharmaceutical companies? View less favourably ...... 4 Please select one option only **SECTION C** – ASK ALL QUALIFYING RESPONDENTS C1. Now just a few questions for classification purposes. Do you work full time, part time or Full time ...... 1 Part time ..... 2 not at all? Not at all ..... 3 C2. Which of these best describes your current marital status? Never married...... 1 Defacto or living together.....2 Married ...... 3 Separated, Divorced or Widowed.... 4 C3. In total, including yourself, how many adults aged 18 years and over live in your household? C4. And how many children aged 17 years or younger live in your household? C5. Into which of these categories does your total household income fall before tax? Under \$30,000 ...... 1 \$30,000 - \$49,999 ...... 2 \$50,000 - \$69,999...... 3 \$70,000 - \$99,999...... 4 \$100.000 or more...... 5 Prefer not to say...... 6

Those are all of the questions. Thank you for your time and participation.





## 4. Detailed Tabular Findings



## Tables

▶ The tables of findings are set out such that they include the following details:

1 BASE: Wght Sample (000s):

The number of completed interviews has been weighted to reflect the latest ABS population estimates. These estimates are shown in thousands (000s). The percentages in the table are based on these weighted figures.

2 **WEIGHTS**:

This indicates that in order to reflect the latest ABS population estimates the data has been weighted by age, gender and area.

3 FILTERS (Where applicable):

If the table is based on a subset of respondents then this will be titled as a Filter and accompanied by a description of the sample upon which the table is based.

4 RESPONDENTS:

These figures show the actual sample size, indicating the total number of respondents who were asked the relevant question.



## Tables ... continued

- **Each question has been analysed by a series of demographic variables as follows:** 
  - $\rightarrow$  SEX:
- Male
- > Female
- → AGE:
- > 18-24 years
- > 25-34 years
- > 35-49 years
- > 50-64 years
- **→** GENERATION:
  - ➤ Gen Y (18-29 years)
  - Gen X (30-44 years)
  - Baby Boomers (45-64 years)
- → MARITAL STATUS:
  - Married (married/de facto/living together)
  - Not married (never married/separated/divorced/widowed)
- → CHILDREN AT HOME:
  - Children under 18 living in the household
  - No children under 18 living in the household



## Tables ... continued

#### **→ WORK STATUS:**

- ➤ Working full-time
- Working part-time
- Not working

#### → LOCATION:

- > NSW
- Victoria / Tasmania
- Queensland
- > South Australia
- Western Australia

#### **→ CAPITAL CITY:**

- > Sydney, Melbourne, Brisbane, Adelaide or Perth
- Rest of Australia

#### **→ HOUSEHOLD INCOME:**

- ➤ Less than \$50K
- > \$50K-\$100K
- ➤ More than \$100K



Banner 1 \*BY\* B1 Approve/ disapprove payment of fees by pharmaceutical companies BASE: WGHT SAMPLE (000s) TABLE 1

|                                   |                       | Se                  | ×                   |                     | Age                 | 9                   |                     | Ger                 | neration            |                     | Marital S    | status              | Childr              | en                  | Wor                 | k Status            | ;                   |
|-----------------------------------|-----------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|--------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
|                                   | Total                 | Male                | Female              | 18-24               | 25-34               | 35-49               | 50-64               | Gen Y               | Gen X               | Baby<br>Boomer      | Marr<br>-ied | Not<br>Marr<br>-ied | Yes                 | No                  | Full<br>Time        | Part<br>Time        | Not<br>Work<br>-ing |
| RESPONDENTS<br>WGHT SAMPLE (000s) | 1007<br>14146<br>100% | 501<br>7006<br>100% | 506<br>7140<br>100% | 111<br>2134<br>100% | 237<br>3036<br>100% | 362<br>4982<br>100% | 297<br>3994<br>100% | 221<br>3514<br>100% | 371<br>5021<br>100% | 415<br>5611<br>100% | !            | 348<br>5109<br>100% | 396<br>5602<br>100% | 611<br>8544<br>100% | 567<br>7788<br>100% | 229<br>3289<br>100% | 211<br>3069<br>100% |
| B1 Approve/ disapprov             | I<br>7e paymer<br>I I | nt of fee           | ا<br>s by pha:<br>ا | rmaceutio           | cal compa           | anies               |                     |                     |                     |                     |              |                     |                     |                     |                     |                     |                     |
| Approve                           | 2901<br>21%           | 1799<br>26%         | 1102<br>15%         | 759<br>36%          | 729<br>24%          | 851<br>17%          | 562<br>14%          |                     | 999<br>20%          | 784<br>14%          | 1732<br>19%  | 1169<br>23%         | 1165<br>21%         | 1736<br>20%         | 1888<br>24%         | 544<br>17%          | 469<br>15%          |
| Disapprove                        | 6283<br>44%           | 3061<br>44%         | 3223<br>45%         | 568<br>27%          | 1131<br>37%         | 2283<br>46%         | 2301<br>58%         | 997<br>28%          | 2284<br>45%         | 3003<br>54%         | 4281<br>47%  | 2003<br>39%         | 2469<br>44%         | 3814<br>45%         | 3387<br>43%         | 1567<br>48%         | 1329<br>43%         |
| Neither/ Don't know               | 4962<br>35%           | 2146<br>31%         | 2816<br>39%         | 807<br>38%          | 1175<br>39%         | 1849<br>37%         | 1131<br>28%         | 1399<br>40%         | 1738<br>35%         | 1825<br>33%         | 3024<br>33%  | 1937<br>38%         | 1968<br>35%         | 2994<br>35%         | 2513<br>32%         | 1179<br>36%         | 1270<br>41%         |
| TOTALS                            | 14146<br>100%         | 7006<br>100%        | 7140<br>100%        | 2134                | 3036<br>100%        | 4982<br>100%        | 3994<br>100%        | 3514<br>100%        | 5021<br>100%        | 5611<br>100%        |              | 5109<br>100%        | 5602<br>100%        | 8544<br>100%        | 7788<br>100%        | 3289<br>100%        | 3069<br>100%        |



TABLE 2 Banner 2 \*BY\* B1 Approve/ disapprove payment of fees by pharmaceutical companies

BASE: WGHT SAMPLE (000s)

|                                   |                       |                      |                     | State               |                    |                    | Capital             | City                | House      | hold Inc            | ome                 |
|-----------------------------------|-----------------------|----------------------|---------------------|---------------------|--------------------|--------------------|---------------------|---------------------|------------|---------------------|---------------------|
|                                   | Total                 | NSW V                | ic/Tas              | QLD                 | SA                 | WA                 | Yes                 | No                  | < \$50K    | \$50K<br>-\$100K    | \$100K+             |
| RESPONDENTS<br>WGHT SAMPLE (000s) | 1007<br>14146<br>100% | 341<br>4927<br>100%  | 305<br>3902<br>100% | 193<br>2813<br>100% | 78<br>1079<br>100% | 90<br>1425<br>100% | 671<br>8856<br>100% | 336<br>5290<br>100% | !          | 333<br>4687<br>100% | 313<br>4314<br>100% |
| B1 Approve/ disapprov             | ı<br>ve paymer<br>I I | ı<br>nt of fees<br>I | by phar             | maceutio            | al compa           | nies               |                     |                     |            |                     |                     |
| Approve                           | 2901<br>21%           | 1079<br>22%          | 727<br>19%          | 624<br>22%          | 211<br>20%         | 259<br>18%         | 2060<br>23%         | 841<br>16%          | 494<br>18% | 1054<br>22%         | 973<br>23%          |
| Disapprove                        | 6283<br>44%           | 2035<br>41%          | 1897<br>49%         | 1256<br>45%         | 426<br>39%         | 669<br>47%         | 3908<br>44%         | 2375<br>45%         |            | 1998<br>43%         | 2093<br>48%         |
| Neither/ Don't know               | 4962<br>35%           | 1813<br>37%          | 1278<br>33%         | 933<br>33%          | 442<br>41%         | 497<br>35%         | 2888<br>33%         | 2074<br>39%         | !          | 1635<br>35%         | 1249<br>29%         |
| TOTALS                            | 14146<br>100%         | 4927<br>100%         | 3902<br>100%        | 2813<br>100%        | 1079               | 1425<br>100%       | 8856<br>100%        | 5290<br>100%        | !          | 4687<br>100%        | 4314<br>100%        |



TABLE 3

Banner 1 \*BY\* B2 Concerns have about pharmaceutical companies paying fees to health care professionals

BASE: WGHT SAMPLE (000s)
WEIGHTS: Area/Age/Sex

|  |                       | Se                  | ×                   |                     | Age                 | <del></del>         |                     | Ge                  | neration            |                     | Marital S           | Status              | Childı              | ren                 | Wor                 | rk Status           |                     |
|--|-----------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
|  | Total                 | Male                | Female              | 18-24               | 25-34               | 35-49               | 50-64               | Gen Y               | Gen X               | Baby<br>Boomer      | Marr<br>-ied        | Not<br>Marr<br>-ied | Yes                 | No                  | Full<br>Time        | Part<br>Time        | Not<br>Work<br>-ing |
| RESPONDENTS<br>WGHT SAMPLE (000s)                          | 1007<br>14146<br>100% | 501<br>7006<br>100% | 506<br>7140<br>100% | 111<br>2134<br>100% | 237<br>3036<br>100% | 362<br>4982<br>100% | 297<br>3994<br>100% | 221<br>3514<br>100% | 371<br>5021<br>100% | 415<br>5611<br>100% | 659<br>9037<br>100% | 348<br>5109<br>100% | 396<br>5602<br>100% | 611<br>8544<br>100% | 567<br>7788<br>100% | 229<br>3289<br>100% | 211<br>3069<br>100% |
| B2 Concerns have abou                                      | l l<br>ut pharma      | <br> ceutical<br>   | <br>  compani<br>   | es payin            | g fees to           | health              | care pr             | <br>rofession:<br>  | als                 |                     |                     |                     |                     |                     |                     |                     |                     |
| It may compromise<br>the integrity of<br>the doctor        | 7660<br>54%           | 3994<br>57%         | 3666<br>51%         | 970<br>45%          | 1490<br>49%         | 2702<br>54%         | 2500<br>63%         | 1669<br>47%         | 2625<br>52%         | 3367<br>60%         | 4956<br>55%         | 2705<br>53%         | 2934<br>52%         | 4726<br>55%         | 4195<br>54%         | 1829<br>56%         | 1636<br>53%         |
| It is not monitored or regulated                           | 6016                  | 3184                | 2832                | 873                 | 1190                | 2073                | 1880                | 1355                | 2067                | 2593                | 3921                | 2095                | 2291                | 3725                | 3476                | 1276                | 1264                |
|  | 43%                   | 45%                 | 40%                 | 41%                 | 39%                 | 42%                 | 47%                 | 39%                 | 41%                 | 46%                 | 43%                 | 41%                 | 41%                 | 44%                 | 45%                 | 39%                 | 41%                 |
| It is a form of bribery                                    | 7243                  | 3654                | 3589                | 982                 | 1366                | 2534                | 2361                | 1497                | 2553                | 3194                | 4703                | 2540                | 2876                | 4368                | 3882                | 1714                | 1647                |
|  | 51%                   | 52%                 | 50%                 | 46%                 | 45%                 | 51%                 | 59%                 | 43%                 | 51%                 | 57%                 | 52%                 | 50%                 | 51%                 | 51%                 | 50%                 | 52%                 | 54%                 |
| It may influence<br>the advice doctors<br>give to patients | 10187<br>72%          | 4941<br>71%         | 5245<br>73%         | 1415<br>66%         | 2166<br>71%         | 3585<br>72%         | 3021<br>76%         | 2327<br>66%         | 3763<br>75%         | 4096<br>73%         | 6760<br>75%         | 3426<br>67%         | 4037<br>72%         | 6150<br>72%         | 5736<br>74%         | 2425<br>74%         | 2026<br>66%         |
| Secret payments are inconsistent with good health care     | 5613                  | 3246                | 2366                | 706                 | 1033                | 1936                | 1937                | 1058                | 1847                | 2707                | 3666                | 1947                | 2168                | 3445                | 3161                | 1192                | 1260                |
|  | 40%                   | 46%                 | 33%                 | 33%                 | 34%                 | 39%                 | 48%                 | 30%                 | 37%                 | 48%                 | 41%                 | 38%                 | 39%                 | 40%                 | 41%                 | 36%                 | 41%                 |
| Patients may not receive the best medicine                 | 7374                  | 3685                | 3689                | 959                 | 1611                | 2569                | 2235                | 1662                | 2574                | 3138                | 4778                | 2596                | 2785                | 4589                | 3964                | 1802                | 1608                |
|  | 52%                   | 53%                 | 52%                 | 45%                 | 53%                 | 52%                 | 56%                 | 47%                 | 51%                 | 56%                 | 53%                 | 51%                 | 50%                 | 54%                 | 51%                 | 55%                 | 52%                 |
| None of the above  | 1195                  | 797                 | 398                 | 223                 | 354                 | 445                 | 172                 | 372                 | 471                 | 352                 | 658                 | 537                 | 427                 | 768                 | 742                 | 173                 | 280                 |
|  | 8%                    | 11%                 | 6%                  | 10%                 | 12%                 | 9%                  | 4%                  | 11%                 | 9%                  | 6%                  | 7%                  | 11%                 | 8%                  | 9%                  | 10%                 | 5%                  | 9%                  |
| TOTALS   | 45288                 | 23502               | 21786               | 6128                | 9210                | 15844               | 14106               | 9940                | 15901               | 19447               | 29442               | 15846               | 17518               | 27770               | 25156               | 10411               | 9721                |
|  | 320%                  | 335%                | 305%                | 287%                | 303%                | 318%                | 353%                | 283%                | 317%                | 347%                | 326%                | 310%                | 313%                | 325%                | 323%                | 317%                | 317%                |



TABLE 4 Banner 2 \*BY\* B2 Concerns have about pharmaceutical companies paying fees to health care professionals BASE: WGHT SAMPLE (000s)

|  |                           |                     | S                   | tate                |                    |                    | Capital             | City                | House          | hold Inc            | ome                 |
|--|---------------------------|---------------------|---------------------|---------------------|--------------------|--------------------|---------------------|---------------------|----------------|---------------------|---------------------|
|  | Total                     | NSW V               | Vic/Tas             | QLD                 | SA                 | WA                 | Yes                 | No                  | < \$50K        | \$50K<br>-\$100K    | \$100K+             |
| RESPONDENTS<br>WGHT SAMPLE (000s)                          | 1007<br>14146<br>100%     | 341<br>4927<br>100% | 305<br>3902<br>100% | 193<br>2813<br>100% | 78<br>1079<br>100% | 90<br>1425<br>100% | 671<br>8856<br>100% | 336<br>5290<br>100% | 2777           | 333<br>4687<br>100% | 313<br>4314<br>100% |
| B2 Concerns have abou                                      | I II<br>ut pharma<br>I II | ceutical            | companies           | paying              | fees to            | health             | l<br>n care pr<br>l | ofession<br>I       | I<br>nals<br>I |                     |                     |
| It may compromise<br>the integrity of<br>the doctor        | 7660<br>54%               | 2746<br>56%         | 2093<br>54%         | 1494<br>53%         | 518<br>48%         | 810<br>57%         | 4647<br>52%         | 3013<br>57%         |                | 2517<br>54%         | 2457<br>57%         |
| It is not monitored or regulated                           | 6016<br>43%               | 2011<br>41%         | 1889<br>48%         | 1019<br>36%         | 405<br>38%         | 692<br>49%         | 3807<br>43%         | 2209<br>42%         | 1091<br>39%    | 1992<br>42%         | 1966<br>46%         |
| It is a form of bribery                                    | 7243<br>51%               | 2548<br>52%         | 2156<br>55%         | 1329<br>47%         | 502<br>46%         | 709<br>50%         | 4567<br>52%         | 2676<br>51%         | 1407<br>51%    | 2508<br>54%         | 2195<br>51%         |
| It may influence<br>the advice doctors<br>give to patients | 10187<br>72%              | 3521<br>71%         | 2869<br>74%         | 1941<br>69%         | 764<br>71%         | 1092<br>77%        | 6381<br>72%         | 3806<br>72%         |                | 3363<br>72%         | 3325<br>77%         |
| Secret payments are inconsistent with good health care     | 5613<br>40%               | 1803<br>37%         | 1585<br>41%         | 1041<br>37%         | 399<br>37%         | 784<br>55%         | 3565<br>40%         | 2047<br>39%         | 1166<br>42%    | 1825<br>39%         | 1784<br>41%         |
| Patients may not<br>receive the best<br>medicine           | 7374<br>52%               | 2524<br>51%         | 2184<br>56%         | 1434<br>51%         | 532<br>49%         | 700<br>49%         | 4541<br>51%         | 2833<br>54%         |                | 2412<br>51%         | 2232<br>52%         |
| None of the above  | 1195<br>8%                | 423<br>9%           | 355<br>9%           | 211<br>7%           | 116<br>11%         | 90<br>6%           | 806<br>9%           | 389<br>7%           | !              | 334<br>7%           | 349<br>8%           |
| TOTALS   | 45288<br>320%             | 15576<br>316%       | 13131<br>337%       | 8468<br>301%        | 3235<br>300%       | 4878<br>342%       | 28314<br>320%       | 16974<br>321%       | 8842<br>318%   | 14949<br>319%       | 14307<br>332%       |



TABLE 5

Funding \*BY\* B3 Approve/ disapprove of pharmaceutical company contributing to cost

BASE: WGHT SAMPLE (000s)

|                                   |                             | Funding  |                                  |                    |
|-----------------------------------|-----------------------------|--|----------------------------------|--------------------|
|                                   | fund<br>medical<br>research | Helping<br>fund<br>clinical<br>education<br>projects | advisory<br>committee<br>work on |                    |
| RESPONDENTS<br>WGHT SAMPLE (000s) | 14146                       | 1007<br>14146<br>100%                                | 14146                            |                    |
| B3 Approve/ disapprov             | <br>ve of pharr<br>         | maceutical   | company co                       | ntributing to cost |
| Approve                           | !!                          | 10070<br>71%   |                                  |                    |
| Disapprove                        | 1123<br>8%                  | 1490<br>11%  |                                  |                    |
| Don't know                        | 1786<br>13%                 | 2586<br>18%  |                                  |                    |
| TOTALS                            |                             | 14146<br>100%  |                                  |                    |



TABLE 6 Banner 1 \*BY\* B3 Approve/ disapprove of pharmaceutical company contributing to cost

BASE: WGHT SAMPLE (000s)

WEIGHTS: Area/Age/Sex

FILTERS: Funding (Helping fund medical research programs)

|                                   |                       | Se                  | ×                   |                     | Age                 | <del></del>         |                     | Ger                 | neration            |                     | Marital S           | Status              | Childr              | en                  | Wor                 | k Status            |                     |
|-----------------------------------|-----------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
|                                   | Total                 | Male                | Female              | 18-24               | 25-34               | 35-49               | 50-64               | Gen Y               | Gen X               | Baby<br>Boomer      | Marr<br>-ied        | Not<br>Marr<br>-ied | Yes                 | No                  | Full<br>Time        | Part<br>Time        | Not<br>Work<br>-ing |
| RESPONDENTS<br>WGHT SAMPLE (000s) | 1007<br>14146<br>100% | 501<br>7006<br>100% | 506<br>7140<br>100% | 111<br>2134<br>100% | 237<br>3036<br>100% | 362<br>4982<br>100% | 297<br>3994<br>100% | 221<br>3514<br>100% | 371<br>5021<br>100% | 415<br>5611<br>100% | 659<br>9037<br>100% | 348<br>5109<br>100% | 396<br>5602<br>100% | 611<br>8544<br>100% | 567<br>7788<br>100% | 229<br>3289<br>100% | 211<br>3069<br>100% |
| B3 Approve/ disapprov             | I<br>ve of pha<br>I I | rmaceuti            | ا<br>cal comp.<br>ا | any contr           | ibuting             | to cost             |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |
| Approve                           | 11238                 | 5485                | 5752                | 1698                | 2332                | 3911                | 3296                | 2840                | 3764                | 4633                | 7306                | 3932                | 4431                | 6807                | 6223                | 2624                | 2390                |
|                                   | 79%                   | 78%                 | 81%                 | 80%                 | 77%                 | 79%                 | 83%                 | 81%                 | 75%                 | 83%                 | 81%                 | 77%                 | 79%                 | 80%                 | 80%                 | 80%                 | 78%                 |
| Disapprove                        | 1123                  | 653                 | 469                 | 159                 | 241                 | 367                 | 355                 | 195                 | 494                 | 434                 | 654                 | 469                 | 375                 | 748                 | 694                 | 225                 | 204                 |
|                                   | 8%                    | 9%                  | 7%                  | 7%                  | 8%                  | 7%                  | 9%                  | 6%                  | 10%                 | 8%                  | 7%                  | 9%                  | 7%                  | 9%                  | 9%                  | 7%                  | 7%                  |
| Don't know                        | 1786                  | 867                 | 918                 | 278                 | 462                 | 703                 | 342                 | 478                 | 764                 | 543                 | 1077                | 708                 | 796                 | 990                 | 871                 | 440                 | 474                 |
|                                   | 13%                   | 12%                 | 13%                 | 13%                 | 15%                 | 14%                 | 9%                  | 14%                 | 15%                 | 10%                 | 12%                 | 14%                 | 14%                 | 12%                 | 11%                 | 13%                 | 15%                 |
| TOTALS                            | 14146                 | 7006                | 7140                | 2134                | 3036                | 4982                | 3994                | 3514                | 5021                | 5611                | 9037                | 5109                | 5602                | 8544                | 7788                | 3289                | 3069                |
|                                   | 100%                  | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                |



TABLE 7 Banner 2 \*BY\* B3 Approve/ disapprove of pharmaceutical company contributing to cost

BASE: WGHT SAMPLE (000s)

WEIGHTS: Area/Age/Sex

FILTERS: Funding (Helping fund medical research programs)

|                                   |                         |                     |                     | State               |                    |                    | Capital            | City                | House        | hold Inc            | ome                 |
|-----------------------------------|-------------------------|---------------------|---------------------|---------------------|--------------------|--------------------|--------------------|---------------------|--------------|---------------------|---------------------|
|                                   | Total                   | NSW V               | ic/Tas              | QLD                 | SA                 | WA                 | Yes                | No                  | < \$50K      | \$50K<br>-\$100K    | \$100K+             |
| RESPONDENTS<br>WGHT SAMPLE (000s) | 1007<br>14146<br>100%   | 341<br>4927<br>100% | 305<br>3902<br>100% | 193<br>2813<br>100% | 78<br>1079<br>100% | 90<br>1425<br>100% | 8856               | 336<br>5290<br>100% | 2777         | 333<br>4687<br>100% | 313<br>4314<br>100% |
| B3 Approve/ disapprov             | ı ı<br>ze of pha<br>I I | rmaceutic           | al compa            | any contr           | ibuting            | to cost            | !<br><u>:</u><br>[ |                     |              |                     |                     |
| Approve                           | 11238<br>79%            | 3841<br>78%         | 2994<br>77%         | 2372<br>84%         | 849<br>79%         | 1181<br>83%        | !                  | 4072<br>77%         | 2229<br>80%  | 3762<br>80%         | 3575<br>83%         |
| Disapprove                        | 1123<br>8%              | 408<br>8%           | 391<br>10%          | 127<br>5%           | 97<br>9%           | 100<br>7%          | !                  | 410<br>8%           | 102<br>4%    | 446<br>10%          | 379<br>9%           |
| Don't know                        | 1786<br>13%             | 678<br>14%          | 517<br>13%          | 314<br>11%          | 133<br>12%         | 143<br>10%         | l .                | 808<br>15%          | 447<br>16%   | 478<br>10%          | 360<br>8%           |
| TOTALS                            | 14146<br>100%           | 4927<br>100%        | 3902<br>100%        | 2813                | 1079               | 1425<br>100%       | !                  | 5290<br>100%        | 2777<br>100% | 4687                | 4314<br>100%        |



TABLE 8 Banner 1 \*BY\* B3 Approve/ disapprove of pharmaceutical company contributing to cost

BASE: WGHT SAMPLE (000s)

WEIGHTS: Area/Age/Sex

FILTERS: Funding(Helping fund clinical education projects)

|                                   |                       | Se                  | ×                   |                     | Age                 | }                   |                     | Ger                 | neration            |                     | Marital S    | Status              | Childr              | en                  | Wor                 | k Status            |                     |
|-----------------------------------|-----------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|--------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
|                                   | Total                 | Male                | Female              | 18-24               | 25-34               | 35-49               | 50-64               | Gen Y               | Gen X               | Baby<br>Boomer      | Marr<br>-ied | Not<br>Marr<br>-ied | Yes                 | No                  | Full<br>Time        | Part<br>Time        | Not<br>Work<br>-ing |
| RESPONDENTS<br>WGHT SAMPLE (000s) | 1007<br>14146<br>100% | 501<br>7006<br>100% | 506<br>7140<br>100% | 111<br>2134<br>100% | 237<br>3036<br>100% | 362<br>4982<br>100% | 297<br>3994<br>100% | 221<br>3514<br>100% | 371<br>5021<br>100% | 415<br>5611<br>100% | 9037         | 348<br>5109<br>100% | 396<br>5602<br>100% | 611<br>8544<br>100% | 567<br>7788<br>100% | 229<br>3289<br>100% | 211<br>3069<br>100% |
| B3 Approve/ disapprov             | I<br>ve of pha<br>I I | ırmaceuti<br>'      | l<br>cal comp.<br>I | any contr           | ibuting             | to cost             |                     |                     |                     |                     |              |                     |                     |                     |                     |                     |                     |
| Approve                           | 10070<br>71%          | 4909<br>70%         | 5160<br>72%         | 1534<br>72%         | 2163<br>71%         | 3424<br>69%         | 2949<br>74%         | 2638<br>75%         | 3290<br>66%         | 4142<br>74%         | !            | 3654<br>72%         | 3948<br>70%         | 6121<br>72%         | 5678<br>73%         | 2347<br>71%         | 2045<br>67%         |
| Disapprove                        | 1490<br>11%           | 923<br>13%          | 567<br>8%           | 261<br>12%          | 310<br>10%          | 525<br>11%          | 394<br>10%          | 333<br>9%           | 654<br>13%          | 503<br>9%           | 925<br>10%   | 565<br>11%          | 526<br>9%           | 964<br>11%          | 915<br>12%          | 342<br>10%          | 233<br>8%           |
| Don't know                        | 2586<br>18%           | 1174<br>17%         | 1413<br>20%         | 339<br>16%          | 563<br>19%          | 1033<br>21%         | 651<br>16%          | 543<br>15%          | 1077<br>21%         | 966<br>17%          | 1696<br>19%  | 890<br>17%          | 1128<br>20%         | 1458<br>17%         | 1195<br>15%         | 601<br>18%          | 791<br>26%          |
| TOTALS                            | 14146<br>100%         | 7006<br>100%        | 7140<br>100%        | 2134<br>100%        | 3036<br>100%        | 4982<br>100%        | 3994<br>100%        | 3514<br>100%        | 5021<br>100%        | 5611<br>100%        | 9037<br>100% | 5109<br>100%        | 5602<br>100%        | 8544<br>100%        | 7788<br>100%        | 3289<br>100%        | 3069<br>100%        |



TABLE 9 Banner 2 \*BY\* B3 Approve/ disapprove of pharmaceutical company contributing to cost

BASE: WGHT SAMPLE (000s)

WEIGHTS: Area/Age/Sex

FILTERS: Funding(Helping fund clinical education projects)

|                                   |                         |                     |                     | State               |                    |                    | Capital             | City                | House        | hold Inc            | ome                 |
|-----------------------------------|-------------------------|---------------------|---------------------|---------------------|--------------------|--------------------|---------------------|---------------------|--------------|---------------------|---------------------|
|                                   | Total                   | NSW V               | ic/Tas              | QLD                 | SA                 | WA                 | Yes                 | No                  | < \$50K      | \$50K<br>-\$100K    | \$100K+             |
| RESPONDENTS<br>WGHT SAMPLE (000s) | 1007<br>14146<br>100%   | 341<br>4927<br>100% | 305<br>3902<br>100% | 193<br>2813<br>100% | 78<br>1079<br>100% | 90<br>1425<br>100% | 671<br>8856<br>100% | 336<br>5290<br>100% | 2777         | 333<br>4687<br>100% | 313<br>4314<br>100% |
| B3 Approve/ disapprov             | ı ı<br>7e of pha<br>I I | ı<br>armaceutic<br> | al compa            | any contr           | ibuting            | to cost            | !<br><u>-</u><br>   |                     |              |                     |                     |
| Approve                           | 10070<br>71%            | 3470<br>70%         | 2758<br>71%         | 2030<br>72%         | 769<br>71%         | 1043<br>73%        | 6448<br>73%         | 3622<br>68%         | !            | 3448<br>74%         | 3095<br>72%         |
| Disapprove                        | 1490<br>11%             | 557<br>11%          | 494<br>13%          | 180<br>6%           | 119<br>11%         | 140<br>10%         | 1003<br>11%         | 487<br>9%           | 150<br>5%    | 459<br>10%          | 596<br>14%          |
| Don't know                        | 2586<br>18%             | 900<br>18%          | 650<br>17%          | 603<br>21%          | 192<br>18%         | 242<br>17%         | 1405<br>16%         | 1182<br>22%         |              | 779<br>17%          | 624<br>14%          |
| TOTALS                            | 14146<br>100%           | 4927<br>100%        | 3902<br>100%        | 2813<br>100%        | 1079<br>100%       | 1425<br>100%       | 8856<br>100%        | 5290<br>100%        | 2777<br>100% | 4687<br>100%        | 4314<br>100%        |



TABLE 10 Banner 1 \*BY\* B3 Approve/ disapprove of pharmaceutical company contributing to cost

BASE: WGHT SAMPLE (000s)

WEIGHTS: Area/Age/Sex

FILTERS: Funding (Funding advisory committee work on new medicines)

|                                   |                       | Se                  | х                   |                     | Age                 | 2                   |                     | Ger                 | neration            |                     | Marital S           | Status              | Childr              | en                  | Wor                 | k Status            |                     |
|-----------------------------------|-----------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
|                                   | Total                 | Male                | Female              | 18-24               | 25-34               | 35-49               | 50-64               | Gen Y               | Gen X               | Baby<br>Boomer      | Marr<br>-ied        | Not<br>Marr<br>-ied | Yes                 | No                  | Full<br>Time        | Part<br>Time        | Not<br>Work<br>-ing |
| RESPONDENTS<br>WGHT SAMPLE (000s) | 1007<br>14146<br>100% | 501<br>7006<br>100% | 506<br>7140<br>100% | 111<br>2134<br>100% | 237<br>3036<br>100% | 362<br>4982<br>100% | 297<br>3994<br>100% | 221<br>3514<br>100% | 371<br>5021<br>100% | 415<br>5611<br>100% | 659<br>9037<br>100% | 348<br>5109<br>100% | 396<br>5602<br>100% | 611<br>8544<br>100% | 567<br>7788<br>100% | 229<br>3289<br>100% | 211<br>3069<br>100% |
| B3 Approve/ disapprov             | <br>ve of pha<br>     | rmaceuti            | cal comp            | any conti           | ributing            | to cost             |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |
| Approve                           | 8324<br>59%           | 4215<br>60%         | 4109<br>58%         | 1330<br>62%         | 1849<br>61%         | 2770<br>56%         | 2375<br>59%         | 2246<br>64%         | 2836<br>56%         | 3242<br>58%         | 5298<br>59%         | 3026<br>59%         | 3248<br>58%         | 5076<br>59%         | 4829<br>62%         | 1843<br>56%         | 1653<br>54%         |
| Disapprove                        | 1983<br>14%           | 1088<br>16%         | 895<br>13%          | 251<br>12%          | 345<br>11%          | 702<br>14%          | 684<br>17%          | 312<br>9%           | 778<br>15%          | 893<br>16%          | 1324<br>15%         | 659<br>13%          | 725<br>13%          | 1258<br>15%         | 1217<br>16%         | 403<br>12%          | 363<br>12%          |
| Don't know                        | 3839<br>27%           | 1703<br>24%         | 2135<br>30%         | 553<br>26%          | 841<br>28%          | 1510<br>30%         | 934<br>23%          | 955<br>27%          | 1407<br>28%         | 1477<br>26%         | 2415<br>27%         | 1424<br>28%         | 1629<br>29%         | 2210<br>26%         | 1742<br>22%         | 1043<br>32%         | 1053<br>34%         |
| TOTALS                            | 14146<br>100%         | 7006<br>100%        | 7140<br>100%        | 2134<br>100%        | 3036<br>100%        | 4982<br>100%        | 3994<br>100%        | 3514<br>100%        | 5021<br>100%        | 5611<br>100%        | ll .                | 5109<br>100%        | 5602<br>100%        | 8544<br>100%        | 7788<br>100%        | 3289<br>100%        | 3069<br>100%        |



TABLE 11 Banner 2 \*BY\* B3 Approve/ disapprove of pharmaceutical company contributing to cost

BASE: WGHT SAMPLE (000s)

WEIGHTS: Area/Age/Sex

FILTERS: Funding (Funding advisory committee work on new medicines)

|                                   |                       |                      |                     | State               |                    |                    | Capital             | City                | House        | hold Inc            | ome                 |
|-----------------------------------|-----------------------|----------------------|---------------------|---------------------|--------------------|--------------------|---------------------|---------------------|--------------|---------------------|---------------------|
|                                   | Total                 | NSW V                | ic/Tas              | QLD                 | SA                 | WA                 | Yes                 | No                  | < \$50K      | \$50K<br>-\$100K    | \$100K+             |
| RESPONDENTS<br>WGHT SAMPLE (000s) | 1007<br>14146<br>100% | 341<br>4927<br>100%  | 305<br>3902<br>100% | 193<br>2813<br>100% | 78<br>1079<br>100% | 90<br>1425<br>100% | 671<br>8856<br>100% | 336<br>5290<br>100% | 2777         | 333<br>4687<br>100% | 313<br>4314<br>100% |
| B3 Approve/ disapprove of ph      |                       | ı<br>armaceutic<br>I | al compa            | any contr           | ibuting            | to cost            | !<br><u>-</u><br>   |                     |              |                     |                     |
| Approve                           | 8324<br>59%           | 2859<br>58%          | 2254<br>58%         | 1674<br>60%         | 585<br>54%         | 952<br>67%         | 5408<br>61%         | 2916<br>55%         | !            | 2869<br>61%         | 2495<br>58%         |
| Disapprove                        | 1983<br>14%           | 700<br>14%           | 586<br>15%          | 383<br>14%          | 138<br>13%         | 176<br>12%         | 1241<br>14%         | 742<br>14%          | !            | 556<br>12%          | 912<br>21%          |
| Don't know                        | 3839<br>27%           | 1368<br>28%          | 1062<br>27%         | 756<br>27%          | 356<br>33%         | 297<br>21%         | 2206<br>25%         | 1632<br>31%         |              | 1262<br>27%         | 907<br>21%          |
| TOTALS                            | 14146<br>100%         | 4927<br>100%         | 3902<br>100%        | 2813<br>100%        | 1079<br>100%       | 1425<br>100%       | 8856<br>100%        | 5290<br>100%        | 2777<br>100% | 4687<br>100%        | 4314<br>100%        |



TABLE 12 Banner 1 \*BY\* Approve of funding

BASE: WGHT SAMPLE (000s)
WEIGHTS: Area/Age/Sex

|  |                       | Se                  | х                   |                     | Age                 | e                   |                     | Gei                 | neration            |                     | Marital             | Status              | Childr              | ren                 | Wor                 | k Status            |                     |
|--|-----------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
|  | Total                 | Male                | Female              | 18-24               | 25-34               | 35-49               | 50-64               | Gen Y               | Gen X               | Baby<br>Boomer      | Marr<br>-ied        | Not<br>Marr<br>-ied | Yes                 | No                  | Full<br>Time        | Part<br>Time        | Not<br>Work<br>-ing |
| RESPONDENTS<br>WGHT SAMPLE (000s)                          | 1007<br>14146<br>100% | 501<br>7006<br>100% | 506<br>7140<br>100% | 111<br>2134<br>100% | 237<br>3036<br>100% | 362<br>4982<br>100% | 297<br>3994<br>100% | 221<br>3514<br>100% | 371<br>5021<br>100% | 415<br>5611<br>100% | 659<br>9037<br>100% | 348<br>5109<br>100% | 396<br>5602<br>100% | 611<br>8544<br>100% | 567<br>7788<br>100% | 229<br>3289<br>100% | 211<br>3069<br>100% |
| Approve of funding   |                       |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |
| TOTAL APPROVE FUNDING<br>RESPONDENTS<br>WGHT SAMPLE (000s) | 830<br>11622<br>82%   | 410<br>5716<br>82%  | 420<br>5907<br>83%  | 93<br>1781<br>83%   | 190<br>2419<br>80%  | 296<br>4045<br>81%  | 251<br>3376<br>85%  | 189<br>2971<br>85%  | 291<br>3925<br>78%  | 350<br>4726<br>84%  | 550<br>7535<br>83%  | 280<br>4087<br>80%  | 325<br>4568<br>82%  | 505<br>7054<br>83%  | 472<br>6474<br>83%  | 191<br>2734<br>83%  | 167<br>2415<br>79%  |
| Helping fund<br>medical research<br>programs               | 11238<br>79%          | 5485<br>78%         | 5752<br>81%         | 1698<br>80%         | 2332<br>77%         | 3911<br>79%         | 3296<br>83%         | 2840<br>81%         | 3764<br>75%         | 4633<br>83%         | 7306<br>81%         | 3932<br>77%         | 4431<br>79%         | 6807<br>80%         | 6223<br>80%         | 2624<br>80%         | 2390<br>78%         |
| Helping fund<br>clinical education<br>projects             | 10070<br>71%          | 4909<br>70%         | 5160<br>72%         | 1534<br>72%         | 2163<br>71%         | 3424<br>69%         | 2949<br>74%         | 2638<br>75%         | 3290<br>66%         | 4142<br>74%         | 6416<br>71%         | 3654<br>72%         | 3948<br>70%         | 6121<br>72%         | 5678<br>73%         | 2347<br>71%         | 2045                |
| Funding advisory<br>committee work on<br>new medicines     | 8324<br>59%           | 4215<br>60%         | 4109<br>58%         | 1330<br>62%         | 1849<br>61%         | 2770<br>56%         | 2375<br>59%         | 2246<br>64%         | 2836<br>56%         | 3242<br>58%         | 5298<br>59%         | 3026<br>59%         | 3248<br>58%         | 5076<br>59%         | 4829<br>62%         | 1843<br>56%         | 1653<br>54%         |
| None   | 2524<br>18%           | 1290<br>18%         | 1233<br>17%         | 353<br>17%          | 617<br>20%          | 937<br>19%          | 618<br>15%          | 543<br>15%          | 1096<br>22%         | 885<br>16%          | 1502<br>17%         | 1022<br>20%         | 1034<br>18%         | 1489<br>17%         | 1315<br>17%         | 555<br>17%          | 654<br>21%          |
| TOTALS   | 32155<br>227%         | 15900<br>227%       | 16255<br>228%       | 4914<br>230%        | 6961<br>229%        | 11041<br>222%       | 9239<br>231%        | 8267<br>235%        | 10986<br>219%       | 12902<br>230%       | 20521<br>227%       | 11634<br>228%       | 12662<br>226%       | 19493<br>228%       | 18044<br>232%       | 7369<br>224%        | 6742<br>220%        |



GALAXY RESEARCH TABLE 13

Banner 2 \*BY\* Approve of funding

BASE: WGHT SAMPLE (000s)
WEIGHTS: Area/Age/Sex

| ,  |                       |                     |                     |                     |                    |                    | ,                   |                     |                    |                     |                     |
|--|-----------------------|---------------------|---------------------|---------------------|--------------------|--------------------|---------------------|---------------------|--------------------|---------------------|---------------------|
|  |                       |                     |                     | State               |                    |                    | Capital             | City                | House              | hold Inc            | ome                 |
|  | Total                 | NSW V               | ic/Tas              | QLD                 | SA                 | WA                 | Yes                 | No                  | < \$50K            | \$50K<br>-\$100K    | \$100K+             |
| RESPONDENTS<br>WGHT SAMPLE (000s)                          | 1007<br>14146<br>100% | 341<br>4927<br>100% | 305<br>3902<br>100% | 193<br>2813<br>100% | 78<br>1079<br>100% | 90<br>1425<br>100% | 671<br>8856<br>100% | 336<br>5290<br>100% | II .               | 333<br>4687<br>100% | 313<br>4314<br>100% |
| Approve of funding   |                       |                     |                     |                     |                    |                    |                     |                     |                    |                     |                     |
| TOTAL APPROVE FUNDING<br>RESPONDENTS<br>WGHT SAMPLE (000s) | 830<br>11622<br>82%   | 281<br>4031<br>82%  | 246<br>3131<br>80%  | 164<br>2389<br>85%  | 63<br>876<br>81%   | 76<br>1195<br>84%  | 562<br>7408<br>84%  | 268<br>4215<br>80%  | 160<br>2265<br>82% | 280<br>3938<br>84%  | 267<br>3686<br>85%  |
| Helping fund<br>medical research<br>programs               | 11238<br>79%          | 3841<br>78%         | 2994<br>77%         | 2372<br>84%         | 849<br>79%         | 1181<br>83%        | 7166<br>81%         | 4072<br>77%         | 2229<br>80%        | 3762<br>80%         | 3575<br>83%         |
| Helping fund<br>clinical education<br>projects             | 10070<br>71%          | 3470<br>70%         | 2758<br>71%         | 2030<br>72%         | 769<br>71%         | 1043<br>73%        | 6448<br>73%         | 3622<br>68%         | 2044<br>74%        | 3448<br>74%         | 3095<br>72%         |
| Funding advisory<br>committee work on<br>new medicines     | 8324<br>59%           | 2859<br>58%         | 2254<br>58%         | 1674<br>60%         | 585<br>54%         | 952<br>67%         | 5408<br>61%         | 2916<br>55%         | 1768<br>64%        | 2869<br>61%         | 2495<br>58%         |
| None   | 2524<br>18%           | 896<br>18%          | 771<br>20%          | 424<br>15%          | 203<br>19%         | 230<br>16%         | 1448<br>16%         | 1075<br>20%         | 512<br>18%         | 749<br>16%          | 628<br>15%          |
| TOTALS   | 32155<br>227%         | 11066<br>225%       | 8777<br>225%        | 6501<br>231%        | 2406<br>223%       | 3406<br>239%       | 20470<br>231%       | 11685<br>221%       | 6552<br>236%       | 10829<br>231%       | 9794<br>227%        |



TABLE 14 Banner 1 \*BY\* B4 Best describes view about pharmaceutical companies paying fees to health care professionals

BASE: WGHT SAMPLE (000s)

|   |                       | Se                  | ×                   |                     | Age                 | )                   |                     | Ger                 | neration            |                     | Marital S           | Status              | Childr              | en                  | Wor                 | k Status            |                     |
|---|-----------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
|   | Total                 | Male                | Female              | 18-24               | 25-34               | 35-49               | 50-64               | Gen Y               | Gen X               | Baby<br>Boomer      | Marr<br>-ied        | Not<br>Marr<br>-ied | Yes                 | No                  | Full<br>Time        | Part<br>Time        | Not<br>Work<br>-ing |
| RESPONDENTS<br>WGHT SAMPLE (000s)   | 1007<br>14146<br>100% | 501<br>7006<br>100% | 506<br>7140<br>100% | 111<br>2134<br>100% | 237<br>3036<br>100% | 362<br>4982<br>100% | 297<br>3994<br>100% | 221<br>3514<br>100% | 371<br>5021<br>100% | 415<br>5611<br>100% | 659<br>9037<br>100% | 348<br>5109<br>100% | 396<br>5602<br>100% | 611<br>8544<br>100% | 567<br>7788<br>100% | 229<br>3289<br>100% | 211<br>3069<br>100% |
| B4 Best describes vie   | <br> wabout<br>       | I<br>pharmace<br>I  | utical c            | ompanies            | paying f            | ees to h            | nealth d            | <br>care profe<br>  | essional            | s                   |                     |                     |                     |                     |                     |                     |                     |
| It is OK because I trust the pharmaceutical companies to do the right thing       | 494                   | 263                 | 230                 | 126                 | 160                 | 145                 | 62                  | 236                 | 169                 | 89                  | 251                 | 242                 | 203                 | 291                 | 225                 | 130                 | 139                 |
|   | 3%                    | 4%                  | 3%                  | 6%                  | 5%                  | 3%                  | 2%                  | 7%                  | 3%                  | 2%                  | 3%                  | 5%                  | 4%                  | 3%                  | 3%                  | 4%                  | 5%                  |
| It is acceptable as long it is completely open and the fees are publicly declared | 9035                  | 4442                | 4593                | 1514                | 2119                | 3156                | 2245                | 2500                | 3238                | 3297                | 5821                | 3213                | 3599                | 5436                | 5129                | 2219                | 1687                |
|   | 64%                   | 63%                 | 64%                 | 71%                 | 70%                 | 63%                 | 56%                 | 71%                 | 64%                 | 59%                 | 64%                 | 63%                 | 64%                 | 64%                 | 66%                 | 67%                 | 55%                 |
| It is not acceptable under any circumstances                                      | 3439                  | 1753                | 1686                | 285                 | 460                 | 1167                | 1526                | 412                 | 1147                | 1880                | 2341                | 1098                | 1386                | 2053                | 1922                | 732                 | 785                 |
|   | 24%                   | 25%                 | 24%                 | 13%                 | 15%                 | 23%                 | 38%                 | 12%                 | 23%                 | 34%                 | 26%                 | 21%                 | 25%                 | 24%                 | 25%                 | 22%                 | 26%                 |
| None of the above   | 1179                  | 548                 | 631                 | 208                 | 297                 | 514                 | 160                 | 367                 | 467                 | 346                 | 624                 | 556                 | 415                 | 764                 | 512                 | 208                 | 459                 |
|   | 8%                    | 8%                  | 9%                  | 10%                 | 10%                 | 10%                 | 4%                  | 10%                 | 9%                  | 6%                  | 7%                  | 11%                 | 7%                  | 9%                  | 7%                  | 6%                  | 15%                 |
| TOTALS  | 14146                 | 7006                | 7140                | 2134                | 3036                | 4982                | 3994                | 3514                | 5021                | 5611                | 9037                | 5109                | 5602                | 8544                | 7788                | 3289                | 3069                |
|   | 100%                  | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                | 100%                |



TABLE 15 Banner 2 \*BY\* B4 Best describes view about pharmaceutical companies paying fees to health care professionals

BASE: WGHT SAMPLE (000s)

|   |                       |                     |                     | State               |                    |                    | Capital             | City                | House              | hold Inc            | come                |
|---|-----------------------|---------------------|---------------------|---------------------|--------------------|--------------------|---------------------|---------------------|--------------------|---------------------|---------------------|
|   | Total                 | NSW V               | /ic/Tas             | QLD                 | SA                 | WA                 | Yes                 | No                  | < \$50K            | \$50K<br>-\$100K    | \$100K+             |
| RESPONDENTS<br>WGHT SAMPLE (000s)   | 1007<br>14146<br>100% | 341<br>4927<br>100% | 305<br>3902<br>100% | 193<br>2813<br>100% | 78<br>1079<br>100% | 90<br>1425<br>100% | 671<br>8856<br>100% | 336<br>5290<br>100% | 2777               | 333<br>4687<br>100% | 313<br>4314<br>100% |
| B4 Best describes vie   | w about"              | pharmaceu           | utical co           | ompanies            | paying             | fees to            | health c            | are pro             | "<br>Fessional<br> | S                   |                     |
| It is OK because I trust the pharmaceutical companies to do the right thing       | 494<br>3%             | 162<br>3%           | 201<br>5%           | 75<br>3%            | 55<br>5%           |                    | 346<br>4%           | 148<br>3%           |                    | 162<br>3%           | 142<br>3%           |
| It is acceptable as long it is completely open and the fees are publicly declared | 9035<br>64%           | 3107<br>63%         | 2548<br>65%         | 1677<br>60%         | 656<br>61%         | 1045<br>73%        | 5883<br>66%         | 3152<br>60%         |                    | 2942<br>63%         | 2977<br>69%         |
| It is not<br>acceptable under<br>any circumstances                                | 3439<br>24%           | 1160<br>24%         | 875<br>22%          | 836<br>30%          | 241<br>22%         | 327<br>23%         | 1995<br>23%         | 1444<br>27%         | 583<br>21%         | 1199<br>26%         | 1061<br>25%         |
| None of the above   | 1179<br>8%            | 497<br>10%          | 278<br>7%           | 224<br>8%           | 127<br>12%         | 53<br>4%           | 633<br>7%           | 546<br>10%          |                    | 383<br>8%           | 134<br>3%           |
| TOTALS  | 14146<br>100%         | 4927<br>100%        | 3902<br>100%        | 2813<br>100%        | 1079<br>100%       | 1425<br>100%       | 8856<br>100%        | 5290<br>100%        | 2777<br>100%       | 4687<br>100%        | 4314<br>100%        |



TABLE 16 Banner 1 \*BY\* B5 Preferred option to make payments more open to scrutiny

BASE: WGHT SAMPLE (000s)
WEIGHTS: Area/Age/Sex

|  |                       | Se                  | ×                   |                     | Age                 | )                   |                     | Gei                 | neration            |                     | Marital S           | Status              | Childr              | en                  | Wor                 | k Status            |                     |
|--|-----------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
|  | Total                 | Male                | Female              | 18-24               | 25-34               | 35-49               | 50-64               | Gen Y               | Gen X               | Baby<br>Boomer      | Marr<br>-ied        | Not<br>Marr<br>-ied | Yes                 | No                  | Full<br>Time        | Part<br>Time        | Not<br>Work<br>-ing |
| RESPONDENTS<br>WGHT SAMPLE (000s)  | 1007<br>14146<br>100% | 501<br>7006<br>100% | 506<br>7140<br>100% | 111<br>2134<br>100% | 237<br>3036<br>100% | 362<br>4982<br>100% | 297<br>3994<br>100% | 221<br>3514<br>100% | 371<br>5021<br>100% | 415<br>5611<br>100% | 659<br>9037<br>100% | 348<br>5109<br>100% | 396<br>5602<br>100% | 611<br>8544<br>100% | 567<br>7788<br>100% | 229<br>3289<br>100% | 211<br>3069<br>100% |
| B5 Preferred option t  | o make p              | n<br>Dayments<br>   | more ope            | en to scru<br>      | ıtiny               |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |                     |
| Reveal total amount<br>spent sponsoring<br>healthcare<br>professionals                         | 3225<br>23%           | 1533<br>22%         | 1692<br>24%         | 691<br>32%          | 892<br>29%          | 934<br>19%          | 707<br>18%          | 1114<br>32%         | 1066<br>21%         | 1045<br>19%         | 1963<br>22%         | 1263<br>25%         | 1314<br>23%         | 1911<br>22%         | 1841<br>24%         | 775<br>24%          | 609<br>20%          |
| Disclose each and<br>every individual<br>sponsorship of<br>specific doctors<br>and specialists | 9223<br>65%           | 4649<br>66%         | 4574<br>64%         | 1045<br>49%         | 1735<br>57%         | 3429<br>69%         | 3013<br>75%         | 1816<br>52%         | 3334<br>66%         | 4073<br>73%         | 6173<br>68%         | 3050<br>60%         | 3632<br>65%         | 5591<br>65%         | 5222<br>67%         | 1996<br>61%         | 2005<br>65%         |
| Don't know   | 1698<br>12%           | 823<br>12%          | 875<br>12%          | 398<br>19%          | 408<br>13%          | 618<br>12%          | 273<br>7%           | 584<br>17%          | 621<br>12%          | 493<br>9%           | 901<br>10%          | 796<br>16%          | 655<br>12%          | 1042<br>12%         | 726<br>9%           | 518<br>16%          | 454<br>15%          |
| TOTALS   | 14146<br>100%         | 7006<br>100%        | 7140<br>100%        | 2134<br>100%        | 3036<br>100%        | 4982<br>100%        | 3994<br>100%        | 3514<br>100%        | 5021<br>100%        | 5611<br>100%        | 9037<br>100%        | 5109<br>100%        | 5602<br>100%        | 8544<br>100%        | 7788<br>100%        | 3289<br>100%        | 3069<br>100%        |



TABLE 17 Banner 2 \*BY\* B5 Preferred option to make payments more open to scrutiny

BASE: WGHT SAMPLE (000s)

|  |                       |                     |                     | State               |                    |                    | Capital             | City                | House        | hold Inc            | ome                 |
|--|-----------------------|---------------------|---------------------|---------------------|--------------------|--------------------|---------------------|---------------------|--------------|---------------------|---------------------|
|  | Total                 | NSW '               | Vic/Tas             | QLD                 | SA                 | WA                 | Yes                 | No                  | < \$50K      | \$50K<br>-\$100K    | \$100K+             |
| RESPONDENTS<br>WGHT SAMPLE (000s)  | 1007<br>14146<br>100% | 341<br>4927<br>100% | 305<br>3902<br>100% | 193<br>2813<br>100% | 78<br>1079<br>100% | 90<br>1425<br>100% | 671<br>8856<br>100% | 336<br>5290<br>100% |              | 333<br>4687<br>100% | 313<br>4314<br>100% |
| B5 Preferred option t  | o make p              | ayments i           | more oper           | n to scr            | utiny              |                    |                     |                     |              |                     |                     |
| Reveal total amount spent sponsoring healthcare professionals                                  | 3225<br>23%           | 1212<br>25%         | 886<br>23%          | 592<br>21%          | 272<br>25%         | 264<br>19%         | 2091<br>24%         | 1134<br>21%         | 749<br>27%   | 1065<br>23%         | 1015<br>24%         |
| Disclose each and<br>every individual<br>sponsorship of<br>specific doctors<br>and specialists | 9223<br>65%           | 3153<br>64%         | 2567<br>66%         | 1865<br>66%         | 649<br>60%         | 989<br>69%         | 5787<br>65%         | 3436<br>65%         | 1709<br>62%  | 3119<br>67%         | 2992<br>69%         |
| Don't know   | 1698<br>12%           | 562<br>11%          | 449<br>12%          | 356<br>13%          | 158<br>15%         | 172<br>12%         | 978<br>11%          | 720<br>14%          |              | 503<br>11%          | 307<br>7%           |
| TOTALS   | 14146<br>100%         | 4927<br>100%        | 3902<br>100%        | 2813<br>100%        | 1079               | 1425<br>100%       | 8856<br>100%        | 5290<br>100%        | 2777<br>100% | 4687<br>100%        | 4314<br>100%        |



TABLE 18 Banner 1 \*BY\* B6 View of pharmaceutical companies if relationships with healthcare professionals were more open

BASE: WGHT SAMPLE (000s)

|   |                       | Se                  | ×x                  |                     | Age                 | 2                   |                     | Ger                 | neration            |                     | Marital S           | Status              | Childr              | en                  | Wor                 | k Status            |                     |
|---|-----------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
|   | Total                 | Male                | Female              | 18-24               | 25-34               | 35-49               | 50-64               | Gen Y               | Gen X               | Baby<br>Boomer      | Marr<br>-ied        | Not<br>Marr<br>-ied | Yes                 | No                  | Full<br>Time        | Part<br>Time        | Not<br>Work<br>-ing |
| RESPONDENTS<br>WGHT SAMPLE (000s)                     | 1007<br>14146<br>100% | 501<br>7006<br>100% | 506<br>7140<br>100% | 111<br>2134<br>100% | 237<br>3036<br>100% | 362<br>4982<br>100% | 297<br>3994<br>100% | 221<br>3514<br>100% | 371<br>5021<br>100% | 415<br>5611<br>100% | 659<br>9037<br>100% | 348<br>5109<br>100% | 396<br>5602<br>100% | 611<br>8544<br>100% | 567<br>7788<br>100% | 229<br>3289<br>100% | 211<br>3069<br>100% |
| B6 View of pharmaceut                                 | ı ı<br>ical com       | I<br>npanies i<br>I | f relati.<br>I      | onships v           | with heal           | lthcare p           | ا<br>professi<br>ا  | onals we            | re more             | open                |                     |                     |                     |                     |                     |                     |                     |
| TOTAL VIEW MORE FAVOU<br>View much more<br>favourably | JRABLY<br>1996<br>14% | 1046<br>15%         | 950<br>13%          | 196<br>9%           | 439<br>14%          | 750<br>15%          | 611<br>15%          | 345<br>10%          | 760<br>15%          | 892<br>16%          | 1304<br>14%         | 692<br>14%          | 844<br>15%          | 1152<br>13%         | 1101<br>14%         | 440<br>13%          | 455<br>15%          |
| View somewhat more<br>favourably                      | 7192<br>51%           | 3637<br>52%         | 3555<br>50%         | 1262<br>59%         | 1495<br>49%         | 2531<br>51%         | 1904<br>48%         | 1982<br>56%         | 2533<br>50%         | 2676<br>48%         | 4685<br>52%         | 2507<br>49%         | 2733<br>49%         | 4459<br>52%         | 4067<br>52%         | 1680<br>51%         | 1445<br>47%         |
| **SUBTOTALS   | 9188<br>65%           | 4683<br>67%         | 4505<br>63%         | 1458<br>68%         | 1934<br>64%         | 3281<br>66%         | 2515<br>63%         | 2327<br>66%         | 3293<br>66%         | 3568<br>64%         | 5989<br>66%         | 3199<br>63%         | 3577<br>64%         | 5611<br>66%         | 5168<br>66%         | 2120<br>64%         | 1900<br>62%         |
| Not change opinion                                    | 4603<br>33%           | 2111<br>30%         | 2492<br>35%         | 523<br>25%          | 1054<br>35%         | 1606<br>32%         | 1420<br>36%         | 1010<br>29%         | 1648<br>33%         | 1946<br>35%         | 2881<br>32%         | 1722<br>34%         | 1884<br>34%         | 2719<br>32%         | 2409<br>31%         | 1141<br>35%         | 1054                |
| View less favourably                                  | 355<br>3%             | 212<br>3%           | 143<br>2%           | 153<br>7%           | 48<br>2%            | 95<br>2%            | 59<br>1%            | 178<br>5%           | 80<br>2%            | 97<br>2%            | 167<br>2%           | 188<br>4%           | 141<br>3%           | 214<br>3%           | 211<br>3%           | 28<br>1%            | 115<br>4%           |
| TOTALS  | 14146<br>100%         | 7006<br>100%        | 7140<br>100%        | 2134<br>100%        | 3036<br>100%        | 4982<br>100%        | 3994<br>100%        | 3514<br>100%        | 5021<br>100%        | 5611<br>100%        | 9037<br>100%        | 5109<br>100%        | 5602<br>100%        | 8544<br>100%        | 7788<br>100%        | 3289<br>100%        | 3069<br>100%        |



JOB:120110A PAGE 19

TABLE 19 Banner 2 \*BY\* B6 View of pharmaceutical companies if relationships with healthcare professionals were more open

BASE: WGHT SAMPLE (000s)

|   |                               |                     |                     | State               |                    |                    | Capital             | City                | House      | hold Inc            | ome                 |
|---|-------------------------------|---------------------|---------------------|---------------------|--------------------|--------------------|---------------------|---------------------|------------|---------------------|---------------------|
|   | Total                         | NSW V               | ic/Tas              | QLD                 | SA                 | WA                 | Yes                 | No                  | < \$50K    | \$50K<br>-\$100K    | \$100K+             |
| RESPONDENTS<br>WGHT SAMPLE (000s)                     | 1007<br>14146<br>100%         | 341<br>4927<br>100% | 305<br>3902<br>100% | 193<br>2813<br>100% | 78<br>1079<br>100% | 90<br>1425<br>100% | 671<br>8856<br>100% | 336<br>5290<br>100% | 2777       | 333<br>4687<br>100% | 313<br>4314<br>100% |
| B6 View of pharmaceut                                 | ical com                      | panies if           | relatio             | onships w           | ith heal           | thcare"            | professi            | onals we            | ere more   | open                |                     |
| TOTAL VIEW MORE FAVOU<br>View much more<br>favourably | <br> RABLY<br>  1996<br>  14% | 632<br>13%          | 505<br>13%          | 448<br>16%          | 159<br>15%         | 252<br>18%         | 1375<br>16%         | 621<br>12%          | 467<br>17% | 768<br>16%          | 624<br>14%          |
| View somewhat more favourably                         | 7192                          | 2648                | 1934                | 1295                | 542                | 773                | 4537                | 2655                | 1374       | 2387                | 2370                |
|   | 51%                           | 54%                 | 50%                 | 46%                 | 50%                | 54%                | 51%                 | 50%                 | 49%        | 51%                 | 55%                 |
| **SUBTOTALS   | 9188                          | 3281                | 2439                | 1743                | 701                | 1025               | 5912                | 3276                | 1841       | 3155                | 2994                |
|   | 65%                           | 67%                 | 62%                 | 62%                 | 65%                | 72%                | 67%                 | 62%                 | 66%        | 67%                 | 69%                 |
| Not change opinion                                    | 4603                          | 1527                | 1337                | 1043                | 352                | 344                | 2701                | 1903                | 813        | 1448                | 1295                |
|   | 33%                           | 31%                 | 34%                 | 37%                 | 33%                | 24%                | 30%                 | 36%                 | 29%        | 31%                 | 30%                 |
| View less favourably                                  | 355                           | 119                 | 127                 | 28                  | 26                 | 55                 | 244                 | 111                 | 123        | 84                  | 26                  |
|   | 3%                            | 2%                  | 3%                  | 1%                  | 2%                 | 4%                 | 3%                  | 2%                  | 4%         | 2%                  | 1%                  |
| TOTALS  | 14146                         | 4927                | 3902                | 2813                | 1079               | 1425               | 8856                | 5290                | 2777       | 4687                | 4314                |
|   | 100%                          | 100%                | 100%                | 100%                | 100%               | 100%               | 100%                | 100%                | 100%       | 100%                | 100%                |





### Intelligent Research Solutions